三阴性乳腺癌免疫治疗的个体化与精准化进展  

Advances in individualization and precision in immunotherapy for triple⁃negative breast cancer

作　　者：严羽欣 张剑 YAN Yuxin;ZHANG Jian(Department of Medical Oncology,Fudan University Shanghai Cancer Center,Shanghai 200032,China;Department of Oncology,Shanghai Medical College,Fudan University,Shanghai 200032,China)

机构地区：[1]复旦大学附属肿瘤医院肿瘤内科,上海200032 [2]复旦大学上海医学院肿瘤学系,上海200032

出　　处：《中国肿瘤外科杂志》2024年第5期429-433,共5页Chinese Journal of Surgical Oncology

基　　金：国家自然科学基金(82072915,82373359)。

摘　　要：三阴性乳腺癌(TNBC)的治疗策略不断更新,并逐步迈入免疫治疗时代。免疫检查点抑制剂(ICI)已被证实在多种恶性肿瘤中具有显著的肿瘤生长抑制作用,但是单药免疫治疗乳腺癌的获益人群十分有限。目前,TNBC免疫治疗的研究主要集中在联合方案(包括化疗联合、靶向联合、放疗联合等)及优势人群的探索。ICI联合其他治疗方法开展了一系列临床研究,相关研究的结果得到了国内外指南的引用和推荐。该文概述了TNBC免疫治疗的临床发展和最新进展,以期为TNBC的个体化和精准化治疗策略提供参考。The treatment strategies for triple negative breast cancer(TNBC)are constantly being updated and are gradually moving into the era of immunotherapy.Immune checkpoint inhibitor(ICI)has been proven to have significant tumor growth inhibitory effects in a variety of malignant tumors,but the benefit population of single⁃agent immunotherapy for breast cancer is minimal.Currently,the research of TNBC immunotherapy mainly focuses on the combination regimen(including chemotherapy combination,targeted combination,radiotherapy combination,etc.)and the exploration of the dominant population.A series of clinical studies have been carried out on ICI in combination with other therapeutic methods,and the results of the relevant studies have been cited and recommended by domestic and international guidelines.This article outlines the clinical development and latest progress of TNBC immunotherapy,aiming to deeply explore the individualization and precision of immunotherapy for triple⁃negative breast cancer,to provide the basis for clinical treatment of breast cancer.

关 键 词：三阴性乳腺癌 免疫治疗 个体化与精准化 联合治疗 

分 类 号：R737.9[医药卫生—肿瘤]